OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Neurology is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China	4728
Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019	685
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza	418
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis	347
Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia	297
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children	287
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome	266
Burden of Neurological Disorders Across the US From 1990-2017	243
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomize	239
Positron Emission Tomography Imaging With [¹⁸F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes	236
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease	230
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy	223
Association of Delirium With Long-term Cognitive Decline	217
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	217
Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry	216
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations	204
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	194
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia	191
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	186
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders	170
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease	170
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals	163
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping	163
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome	158
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β	150

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens	146
Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy	144
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel	140
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease	140
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease	140
The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection	138
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex	136
Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans	135
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	133
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy	132
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	131
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab	129
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study	128
Association Between Cardiovascular Disease and Long-term Exposure to Air Pollution With the Risk of Dementia	126
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis	124
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	124
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	121
Global Prevalence of Young-Onset Dementia	119
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	116
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	114
Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis	113
Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome	113
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	108
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes	107
Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults	106
Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders	105
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease	105
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease	103
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	101
Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated Stroke	100
Global Prevalence and Incidence of Tinnitus	99
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	98
Assessment of the Predictive Value of Outpatient Smartphone Videos for Diagnosis of Epileptic Seizures	96
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	94
Association of Time Since Injury to the First Clinic Visit With Recovery Following Concussion	94
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study	94
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis	91
Seizure Cycles in Focal Epilepsy	90
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome	89
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders	87
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	87
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets	86
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	86
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension	85
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis	85
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes	85
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis	84
Blood Pressure Thresholds and Neurologic Outcomes After Endovascular Therapy for Acute Ischemic Stroke	81
Continuous vs Routine Electroencephalogram in Critically Ill Adults With Altered Consciousness and No Recent Seizure	81
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability	81

Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US	80
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease	80
Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke	77